Testing and Interpretation of Human Epidermal Growth Factor Receptor 2 Protein Expression and <i>ERBB2</i> Gene Amplification in Advanced Urothelial Carcinoma
We observed that more than 50% of 2,024 advanced UC tumors demonstrated some degree of HER2 protein expression detected using a standardized IHC method, whereas about 12% of specimens had <i>ERBB2</i> gene amplification, including about 3% of those scored as either IHC 0 or 1+. Continued development of optimized and standardized HER2 testing methods is warranted to identify patients with HER2-expressing UC who may benefit from novel HER2-targeting therapies.
Authors
- Christine Boyiddle
- Farzaneh Sayedian (ORCID: https://orcid.org/0000-0002-6336-1319)
- Vadim S. Koshkin (ORCID: https://orcid.org/0000-0003-2277-8668)
- Emily Chan (ORCID: https://orcid.org/0000-0002-7290-4004)
- Naomi Schwartz (ORCID: https://orcid.org/0000-0003-0656-7801)
- Johanna M. Schafer (ORCID: https://orcid.org/0000-0001-7834-5621)
- Emilie Scherrer (ORCID: https://orcid.org/0000-0003-3184-3724)
- Amanda F. Baker (ORCID: https://orcid.org/0000-0002-0670-5381)
- Qijun Fang
- Hong Yu
Institutions
- Roche (United States) (US)
- University of California, San Francisco (US)
- Pfizer (United States) (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- Stanford University (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-04-16
- DOI
- https://doi.org/10.1200/po-24-00879
- Citations
- 5
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 10.03